GSK· @GSK · X·· 2026-07-28精选AI 评分60
AI 导读
GSK宣布在AIDS2026公布首个随机头对头研究的新数据，该研究在初治成人中比较每日口服两药方案与三药方案。相关详情见其新闻稿，研究由其专科HIV公司ViiVHC开展。
推荐理由
原文披露了首个每日口服两药方案与三药方案在初治成人中的随机头对头研究数据，可据此了解HIV简化治疗方案的证据进展。
正文
#News for #Investors and #Media: We are announcing new data from the first randomised head-to-head study comparing daily oral 2-drug regimen vs 3-drug regimen in treatment-naïve adults at #AIDS2026.
🔗 Find out more in the press release: https://gsk.to/44QBFUg
Through our specialist HIV company, @ViiVHC, our goal is to empower individuals and communities, driving towards a future where HIV is no longer a global health threat.
来源：GSK · x.com